2024-09-07 - Analysis Report
## REGN Stock Analysis Report

**Company:** Regeneron Pharmaceuticals, Inc. (REGN) - A biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance Relative to S&P 500:**

* **REGN Cumulative Return:** 157.56%
* **VOO (S&P 500) Cumulative Return:** 84.86%
* **Difference:** 72.70%
* **Relative Divergence:** 95.82% (This indicates that REGN's performance has outpaced the S&P 500 by a significant margin, ranking in the 95.82nd percentile of its historical performance relative to the benchmark.)

**2. Recent Price Movement:**

* **Closing Price:** $1179.37
* **5-Day Moving Average:** $1182.22
* **20-Day Moving Average:** $1168.84
* **60-Day Moving Average:** $1095.92

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 59.15 (Indicates that the stock is in a neutral zone, neither overbought nor oversold.)
* **PPO (Percentage Price Oscillator):** -0.42 (Indicates a slight bearish bias in the short term, but it's a relatively weak signal.)
* **Delta_Previous_Relative_Divergence:** -4.18 (Suggests a short-term downward trend in the relative performance compared to the benchmark.)
* **Expected Return:** 3.13% (Represents the potential 5-year return based on current investment levels.)

**4. Recent Earnings & Outlook:**

| Date       | EPS       | Revenue      |
|-------------|------------|--------------|
| 2024-08-01 | 13.25     | $3.55 B$      |
| 2024-05-02 | 6.7       | $3.15 B$      |
| 2023-11-02 | 9.48      | $3.36 B$      |
| 2023-08-03 | 9.05      | $3.16 B$      |
| 2024-08-01 | 9.05      | $3.16 B$      |

**Analysis:**

Regeneron has consistently exceeded revenue expectations, exhibiting strong growth. The most recent earnings report (2024-08-01) showed a significant increase in EPS, exceeding analyst estimates. This positive trend in earnings indicates strong underlying business performance and a positive outlook for the future.

**5. Overall Analysis:**

Regeneron has outperformed the S&P 500 by a considerable margin, displaying strong historical performance. Despite a recent slight short-term downward trend in relative performance, the technical indicators suggest a neutral to bullish sentiment. The company's consistent revenue growth and strong recent earnings signal a promising future. 

**6. Conclusion:**

Based on the analysis, REGN appears to be a solid investment with a strong track record of growth and a promising future. While short-term technical indicators point to a minor slowdown, the company's fundamental performance continues to impress. Investors seeking long-term growth in the biotechnology sector may want to consider REGN for their portfolio. 
